The Evolving Therapeutic Landscape in Sjögren’s Disease: From Pathophysiology to Clinical Evidence
Objectives:
Sjögren’s disease carries a profound clinical and psychosocial burden, frequently compounded by delayed diagnosis and inadequate conventional treatments. This live symposium will explore the unmet needs and pathophysiology of Sjögren’s disease, focusing on the central role of B-cell hyperactivity and the rationale for B-cell depletion. Expert faculty will review the mechanisms of action and key clinical data for emerging targeted B-cell depleting therapies that are expanding the therapeutic landscape. Join us for an exciting and interactive discussion on this new generation of biologics that promise to shift the clinical paradigm from simple symptom management toward true disease modification.
This session is supported by independent funding from Novartis.
| Agenda - Friday 30 October | |
|---|---|
|
|
Chairperson: Prof Maureen Rischmueller, Australia
|
|
1730-1742
|
Diagnostic Challenges and Unmet Needs in Sjögren’s Disease
Prof Maureen Rischmueller, Australia |
|
1742-1750 |
Pathophysiology of Sjögren’s Disease: The Case for B-Cell Depletion
Prof Maureen Rischmueller, Australia Dr Pilar Brito-Zerón, Spain |
|
1750-1820 |
A New Generation of Biologics: Mechanism of Action and Key Clinical Data Prof Maureen Rischmueller, Australia Dr Pilar Brito-Zerón, Spain |
|
1820-1825
|
Looking to the Future: From Trial Data to Clinical Practice Prof Maureen Rischmueller, Australia Dr Pilar Brito-Zerón, Spain |
|
1825 |
Concluding Remarks and Evaluation Prof Maureen Rischmueller, Australia |
